PURE Bioscience Reports Fiscal Second Quarter 2026 Financial Results

EL CAJON, Calif.--(BUSINESS WIRE)---- $PURE #Antimicrobial--PURE Bioscience, Inc. (OTCQB: PURE) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal second quarter ended January 31, 2026. Summary of Results – Fiscal Second Quarter Operations Net product sales were $443,000 and $391,000 for the fiscal second quarters ended January 31, 2026 and 2025, respectively. The increase of $52,000 was attributable to increa.